Nathaniel Wachter, MD
Neurology · Saint Louis, MONPI 1922492123
Payments from drug & device makers
Across 325 payments — averaging $84.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$16K
- Boston Scientific$5K
- AbbVie$3K
- Supernus Pharmaceuticals, Inc.$669
- Lilly USA, LLC$403
- UCB, Inc.$393
- plus $2K from 33 others
What the payments were for
- Grants$20,00073%
- Food & beverage$7,36127%
- Education$110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 23 | $15,558 |
| Boston Scientific | 2 | $5,130 |
| AbbVie(2 entities) | 147 | $2,748 |
| Supernus Pharmaceuticals, Inc. | 8 | $669 |
| Lilly USA, LLC | 21 | $403 |
| UCB, Inc. | 12 | $393 |
| Biogen | 13 | $281 |
| MDD US Operations, LLC | 9 | $257 |
| Pfizer | 10 | $173 |
| Lundbeck LLC | 4 | $165 |
| Novartis | 8 | $149 |
| Neurelis, Inc. | 8 | $146 |
| EMD Serono, Inc. | 6 | $116 |
| Teva Pharmaceuticals USA, Inc. | 5 | $104 |
| Argenx US, Inc. | 4 | $96 |
| Sumitomo Pharma America, Inc. | 4 | $92 |
| AstraZeneca(2 entities) | 4 | $91 |
| Neurocrine Biosciences, Inc. | 3 | $81 |
| Catalyst Pharmaceuticals, Inc. | 3 | $73 |
| Grifols USA, LLC | 3 | $66 |
| Amneal Pharmaceuticals LLC | 3 | $66 |
| Xeris Pharmaceuticals, Inc. | 3 | $60 |
| Amgen | 3 | $54 |
| TG Therapeutics, Inc. | 2 | $48 |
| Acorda Therapeutics, Inc | 2 | $40 |
| Jazz Pharmaceuticals Inc. | 1 | $34 |
| Genentech USA, Inc. | 2 | $33 |
| CSL Behring | 1 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $30 |
| Sanofi | 1 | $28 |
| SK Life Science, Inc. | 1 | $26 |
| Axsome Therapeutics, Inc. | 1 | $25 |
| Acadia Pharmaceuticals Inc | 1 | $18 |
| Impel Pharmaceuticals Inc. | 1 | $17 |
| Averitas Pharma Inc. | 1 | $17 |
| Kyowa Kirin, Inc. | 1 | $14 |
| Merz Pharmaceuticals, LLC | 1 | $13 |
| Currax Pharmaceuticals LLC | 1 | $13 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACTIVA$15,000
- SPECTRA WAVEWRITER$5,000
- QELBREE$539
- GENERAL DBS$130
- APOKYN$122
How this compares
$27,372 in reported general payments places this provider in the 75th percentile of 381 neurology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 18 | $96,956 |
| NuplazidPimavanserin Tartrate | 17 | $83,653 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 1,078 | $40,872 |
| RytaryCarbidopa/Levodopa | 37 | $37,582 |
| Emgality PenGalcanezumab-Gnlm | 19 | $18,519 |
| UbrelvyUbrogepant | 12 | $12,083 |
| RivastigmineRivastigmine Tartrate | 116 | $9,474 |
| Rivastigmine | 63 | $7,118 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 152 | $6,138 |
| Propranolol Hcl ErPropranolol Hcl | 144 | $5,416 |
| Entacapone | 28 | $5,213 |
| Selegiline Hcl | 44 | $5,140 |
| Rasagiline Mesylate | 35 | $4,259 |
| AmantadineAmantadine Hcl | 85 | $4,076 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 100 | $2,871 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $104 | $96,95618 claims |
| Acadia Pharmaceuticals IncNuplazid | $18 | $83,65317 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $66 | $38,17648 claims |
| AbbVieUbrelvy | $2,748 | $12,08312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 381 neurology providers in Missouri.
Other neurology in Saint Louis
- Randall BatemanSaint Louis$92.3M
- David HoltzmanSaint Louis$25.2M
- Robert NaismithSaint Louis$13.8M
- Eric McDadeSaint Louis$9.6M
- Robert BucelliSaint Louis$8.5M
- Barbara SniderSaint Louis$7M
- Gregory WuSaint Louis$5.7M
- Barry SingerSaint Louis$3.3M
- Mark TullmanSaint Louis$2.3M
- Suzanne SchindlerSaint Louis$2.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.